Could Dendreon Be a Buyout Candidate?

Before you go, we thought you'd like these...
Before you go close icon

In the video below, Fool analysts David Williamson and Max Macaluso discuss drugmaker Dendreon as a possible takeover target in 2013.

While hope of a buyout has diminished as Dendreon's struggles mounted, the possibility still exists. However, there is one additional hurdle that might keep big pharma away from Dendreon, which investors are not talking about.


Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors -- other than a bit nauseous from the roller-coaster ride? David answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.

The article Could Dendreon Be a Buyout Candidate? originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Follow him on Twitter @MotleyDavidMax Macaluso has no position in any stocks mentioned. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners